Cargando…

Hepatic perivascular epithelioid cell tumor: A case report

BACKGROUND: Perivascular epithelioid cell tumor (PEComa) is a mesenchymal tumor with histologic and immunophenotypic characteristics of perivascular epithelioid cells, has a low incidence, and can involve multiple organs. PEComa originating in the liver is extremely rare, with most cases being benig...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yong-Fang, Wang, Liang, Xie, Yi-Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131209/
https://www.ncbi.nlm.nih.gov/pubmed/35665123
http://dx.doi.org/10.12998/wjcc.v10.i13.4273
_version_ 1784713136139403264
author Li, Yong-Fang
Wang, Liang
Xie, Yi-Jing
author_facet Li, Yong-Fang
Wang, Liang
Xie, Yi-Jing
author_sort Li, Yong-Fang
collection PubMed
description BACKGROUND: Perivascular epithelioid cell tumor (PEComa) is a mesenchymal tumor with histologic and immunophenotypic characteristics of perivascular epithelioid cells, has a low incidence, and can involve multiple organs. PEComa originating in the liver is extremely rare, with most cases being benign, and only a few cases are malignant. Good outcomes are achieved with radical surgical resection, but there is no effective treatment for some large tumors and specific locations that are contraindicated for surgery. CASE SUMMARY: A 32-year-old woman was admitted to our hospital with a palpable abdominal mass and progressive deterioration since the previous month. An ultrasound-guided percutaneous liver aspiration biopsy was performed. Postoperative pathological immunohistochemical staining was HMB45, Melan-A, and smooth muscle actin positive. Perivascular epithelioid tumor was diagnosed. The tumor was large and could not be completely resected by surgery. Further digital subtraction angiography revealed a rich tumor blood supply, and interventional embolization followed by surgery was recommended. Finally, the patient underwent transarterial embolization (TAE) combined with sorafenib for four cycles. Angiography reexamination indicated no clear vascular staining of the tumor, and the tumor had shrunk. The patient was followed up for a short period of time, achieved a stable condition, and surgery was recommended. CONCLUSION: Adjuvant combination treatment with TAE and sorafenib is safe and feasible as it shrinks the tumor preoperatively and facilitates surgery.
format Online
Article
Text
id pubmed-9131209
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-91312092022-06-04 Hepatic perivascular epithelioid cell tumor: A case report Li, Yong-Fang Wang, Liang Xie, Yi-Jing World J Clin Cases Case Report BACKGROUND: Perivascular epithelioid cell tumor (PEComa) is a mesenchymal tumor with histologic and immunophenotypic characteristics of perivascular epithelioid cells, has a low incidence, and can involve multiple organs. PEComa originating in the liver is extremely rare, with most cases being benign, and only a few cases are malignant. Good outcomes are achieved with radical surgical resection, but there is no effective treatment for some large tumors and specific locations that are contraindicated for surgery. CASE SUMMARY: A 32-year-old woman was admitted to our hospital with a palpable abdominal mass and progressive deterioration since the previous month. An ultrasound-guided percutaneous liver aspiration biopsy was performed. Postoperative pathological immunohistochemical staining was HMB45, Melan-A, and smooth muscle actin positive. Perivascular epithelioid tumor was diagnosed. The tumor was large and could not be completely resected by surgery. Further digital subtraction angiography revealed a rich tumor blood supply, and interventional embolization followed by surgery was recommended. Finally, the patient underwent transarterial embolization (TAE) combined with sorafenib for four cycles. Angiography reexamination indicated no clear vascular staining of the tumor, and the tumor had shrunk. The patient was followed up for a short period of time, achieved a stable condition, and surgery was recommended. CONCLUSION: Adjuvant combination treatment with TAE and sorafenib is safe and feasible as it shrinks the tumor preoperatively and facilitates surgery. Baishideng Publishing Group Inc 2022-05-06 2022-05-06 /pmc/articles/PMC9131209/ /pubmed/35665123 http://dx.doi.org/10.12998/wjcc.v10.i13.4273 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Case Report
Li, Yong-Fang
Wang, Liang
Xie, Yi-Jing
Hepatic perivascular epithelioid cell tumor: A case report
title Hepatic perivascular epithelioid cell tumor: A case report
title_full Hepatic perivascular epithelioid cell tumor: A case report
title_fullStr Hepatic perivascular epithelioid cell tumor: A case report
title_full_unstemmed Hepatic perivascular epithelioid cell tumor: A case report
title_short Hepatic perivascular epithelioid cell tumor: A case report
title_sort hepatic perivascular epithelioid cell tumor: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131209/
https://www.ncbi.nlm.nih.gov/pubmed/35665123
http://dx.doi.org/10.12998/wjcc.v10.i13.4273
work_keys_str_mv AT liyongfang hepaticperivascularepithelioidcelltumoracasereport
AT wangliang hepaticperivascularepithelioidcelltumoracasereport
AT xieyijing hepaticperivascularepithelioidcelltumoracasereport